RT Eric Topol: For treatment and outcomes for cancer, the tumor microenvironment (TME) is pivotal, but we've never had a non-invasive way to assess it...
A new blood test breakthrough now allows non-invasive assessment of the tumor microenvironment (TME), which is crucial for cancer treatment and outcomes. The TME consists of immune cells, blood vessel cells, fibroblasts, and matrix surrounding cancer cells.
Background
- Eric Topol is a prominent cardiologist, genetic researcher, and author (e.g., *The Creative Destruction of Medicine*) who often shares breakthrough medical research on Twitter.
- The tumor microenvironment (TME) is the ecosystem of non-cancerous cells, blood vessels, immune cells, and connective tissue surrounding a tumor. It heavily influences whether a cancer grows, spreads, or responds to treatment.
- Until now, analyzing the TME required a tissue biopsy (invasive, risky, often impossible to repeat). A "liquid biopsy" blood test that can read TME signals non-invasively would be a major advance for guiding immunotherapy and other treatments in real time.
- The claim of a "breakthrough" is notable coming from Topol, who is typically cautious with that word.